Skip to main content
OTCMKTS:MBVXQ

MabVax Therapeutics Competitors

$0.02
+0.00 (+9.52 %)
(As of 03/19/2020)
Add
Compare
Today's Range
$0.02
$0.02
50-Day Range
$0.02
$0.02
52-Week Range
$0.00
$0.30
Volume1,300 shs
Average Volume17,571 shs
Market Capitalization$212,865.00
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

MabVax Therapeutics (OTCMKTS:MBVXQ) Vs. ACUS, AFFY, ARYX, AHROQ, CBPI, and CDSG

Should you be buying MBVXQ stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to MabVax Therapeutics, including Acusphere (ACUS), Affymax (AFFY), ARYx Therapeutics (ARYX), AtheroNova (AHROQ), China Botanic Pharmaceutical (CBPI), and China Dongsheng International (CDSG).

MabVax Therapeutics (OTCMKTS:MBVXQ) and Acusphere (OTCMKTS:ACUS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings and valuation.

Profitability

This table compares MabVax Therapeutics and Acusphere's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MabVax TherapeuticsN/AN/AN/A
AcusphereN/AN/AN/A

Valuation & Earnings

This table compares MabVax Therapeutics and Acusphere's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MabVax TherapeuticsN/AN/AN/AN/AN/A
AcusphereN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings for MabVax Therapeutics and Acusphere, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MabVax Therapeutics0000N/A
Acusphere0000N/A

MabVax Therapeutics (OTCMKTS:MBVXQ) and Affymax (OTCMKTS:AFFY) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations and earnings.

Profitability

This table compares MabVax Therapeutics and Affymax's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MabVax TherapeuticsN/AN/AN/A
AffymaxN/AN/AN/A

Valuation and Earnings

This table compares MabVax Therapeutics and Affymax's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MabVax TherapeuticsN/AN/AN/AN/AN/A
AffymaxN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of current recommendations and price targets for MabVax Therapeutics and Affymax, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MabVax Therapeutics0000N/A
Affymax0000N/A

MabVax Therapeutics (OTCMKTS:MBVXQ) and ARYx Therapeutics (OTCMKTS:ARYX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations and earnings.

Profitability

This table compares MabVax Therapeutics and ARYx Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MabVax TherapeuticsN/AN/AN/A
ARYx TherapeuticsN/AN/AN/A

Valuation and Earnings

This table compares MabVax Therapeutics and ARYx Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MabVax TherapeuticsN/AN/AN/AN/AN/A
ARYx TherapeuticsN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of current recommendations and price targets for MabVax Therapeutics and ARYx Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MabVax Therapeutics0000N/A
ARYx Therapeutics0000N/A

MabVax Therapeutics (OTCMKTS:MBVXQ) and AtheroNova (OTCMKTS:AHROQ) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations and earnings.

Profitability

This table compares MabVax Therapeutics and AtheroNova's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MabVax TherapeuticsN/AN/AN/A
AtheroNovaN/AN/AN/A

Valuation and Earnings

This table compares MabVax Therapeutics and AtheroNova's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MabVax TherapeuticsN/AN/AN/AN/AN/A
AtheroNovaN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of current recommendations and price targets for MabVax Therapeutics and AtheroNova, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MabVax Therapeutics0000N/A
AtheroNova0000N/A

MabVax Therapeutics (OTCMKTS:MBVXQ) and China Botanic Pharmaceutical (OTCMKTS:CBPI) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations and earnings.

Analyst Recommendations

This is a summary of current recommendations and price targets for MabVax Therapeutics and China Botanic Pharmaceutical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MabVax Therapeutics0000N/A
China Botanic Pharmaceutical0000N/A

Valuation and Earnings

This table compares MabVax Therapeutics and China Botanic Pharmaceutical's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MabVax TherapeuticsN/AN/AN/AN/AN/A
China Botanic PharmaceuticalN/AN/AN/AN/AN/A

Profitability

This table compares MabVax Therapeutics and China Botanic Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MabVax TherapeuticsN/AN/AN/A
China Botanic PharmaceuticalN/AN/AN/A

China Dongsheng International (OTCMKTS:CDSG) and MabVax Therapeutics (OTCMKTS:MBVXQ) are both consumer staples companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, analyst recommendations and valuation.

Valuation & Earnings

This table compares China Dongsheng International and MabVax Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China Dongsheng InternationalN/AN/AN/AN/AN/A
MabVax TherapeuticsN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and target prices for China Dongsheng International and MabVax Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
China Dongsheng International0000N/A
MabVax Therapeutics0000N/A

Profitability

This table compares China Dongsheng International and MabVax Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
China Dongsheng InternationalN/AN/AN/A
MabVax TherapeuticsN/AN/AN/A


MabVax Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Acusphere logo
ACUS
Acusphere
0.0$0.05+24.4%$0.00N/A0.00Gap Up
Affymax logo
AFFY
Affymax
0.6$0.08+0.0%$0.00N/A0.00Gap Down
ARYX
ARYx Therapeutics
0.0$0.01+0.7%$0.00N/A0.00
AHROQ
AtheroNova
0.0$0.01+0.0%$0.00N/A0.00
CBPI
China Botanic Pharmaceutical
0.0$0.08+6.0%$0.00N/A0.00Gap Down
China Dongsheng International logo
CDSG
China Dongsheng International
0.3$0.05+19.2%$0.00N/A0.00Gap Down
China Health Industries logo
CHHE
China Health Industries
0.4$0.25+0.0%$0.00$9.93 million4.20
DDXSQ
Diadexus
0.0$0.00+0.0%$0.00N/A0.00
ERBA
ERBA Diagnostics
0.8$0.04+0.0%$0.00N/A0.00
FTCY
Global Future City
0.5$0.00+0.0%$0.00N/A0.00
GLSI
Greenwich LifeSciences
2.0$31.69+3.8%$0.00N/A0.00
HRBR
Harbor Diversified
0.0$1.90+10.5%$0.00$263.61 million0.00Gap Up
IPAH
Interpharm
0.2$0.00+0.0%$0.00N/A0.00
IRBS
IR Biosciences
0.0$0.00+0.0%$0.00N/A0.00
MYRX
Myrexis
0.5$0.05+0.0%$0.00N/A0.00Gap Down
NNBP
Nanobac Pharmaceuticals
0.0$0.00+100.0%$0.00N/A0.00Gap Down
PARD
Poniard Pharmaceuticals
0.5$0.09+0.0%$0.00N/A0.00
SGTI
Shengtai Pharmaceutical
0.2$0.02+0.0%$0.00N/A0.00
SKBI
Skystar Bio-Pharmaceutical
0.5$0.00+0.0%$0.00N/A0.00
SUWN
Sunwin Stevia International
0.5$0.05+0.0%$0.00$26.09 million0.00
Sycamore Entertainment Group logo
SEGI
Sycamore Entertainment Group
0.3$0.03+0.0%$0.00N/A0.00
SYNI
Synvista Therapeutics
0.0$0.00+0.0%$0.00N/A0.00
TPIY
Tianyin Pharmaceutical
0.6$0.00+0.0%$0.00N/A0.00High Trading Volume
Tibet Pharmaceuticals logo
TBET
Tibet Pharmaceuticals
0.0$0.01+3.0%$0.00N/A0.00High Trading Volume
Gap Down
VOQP
VioQuest Pharmaceuticals
0.0$0.01+0.0%$0.00N/A0.00
This page was last updated on 5/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.